Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Mon, 29th Mar 2021 09:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Destiny Pharma PLC, up 27% at 203.20 pence, 12-month range 29.1p-250p. 12-month high was hit earlier on Monday. The biotechnology firm reports data which found its nasal gel may be effective in preventing post-surgical bacterial infections. Results from a Phase 2b trial of XF-73 meet the primary efficacy endpoint. It shows a 99.5% decline in staphylococcus aureus bacterial nasal carriage, a "very effective reduction by accepted clinical measures", Destiny says. Compared to a placebo, it shows a greater than 99% reduction.

----------

Europa Metals Ltd, up 13% at 12.98p, 12-month range 4.25p-30.00p. The Australian mining projects developer reports a widened interim pretax loss but says there does not currently appear to be any material impact on the company or any significant uncertainties as a result of the coronavirus pandemic. Posts pretax loss of AUD1.7 million - about USD1.3 million - for the six months to the end of 2020, compared to AUD1.4 million loss a year earlier.

----------

Blackbird PLC, up 10% at 26.95p, 12-month range 9.5p-29.65p. The developer and seller of cloud video editing platforms says BT has chosen it for "ultra-fast and sustainable" cloud native video editing and publishing. Blackbird will work in conjunction with Pete Harvey, BT's head of digital media content operations. Harvey will use Blackbird to access and edit multiple live broadcast streams of sports and other content for the "fast" production of assets for downstream distribution to over the top and video on demand channels.

----------

AIM - LOSERS

----------

RA International Group PLC, down 16% at 41.24p, 12-month range 27.2p-72.5p. The remote site services provider notes a further escalation in hostile activity in the Cabo Delgado province, northern Mozambique, near to where the company's operations are based. Says security concerns, compounded by the pandemic and extreme weather, have led to delays to the overall energy related project in the region and to the suspension of its contract to build and operate an 1,800-person camp, where an extension of the initial two-year tenancy contract is under negotiation. "Given the escalation in hostilities in the area in recent days, the directors of the company now expect there will be further delays in the project that are likely to impact on the overall financial performance of the company in the current financial year. This impact is expected, at the current time, to be up to USD10 million of revenue, which the directors expect will now be recognised in a later financial period," says Chief Executive Soraya Narfeldt.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Oct 2020 14:42

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

Read more
12 Oct 2020 14:31

Second Covid wave slows patient recruitment for Destiny Pharma

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its 'XF-73' phase 2b clinical study with 101 patients on Monday, out of the target of 125 now recruited.

Read more
17 Sep 2020 19:09

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

Read more
17 Sep 2020 15:39

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

Read more
7 Sep 2020 14:34

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

Read more
7 Sep 2020 08:57

Destiny Pharma enters collaboration deal with SporeGen

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has entered into a collaboration agreement with SporeGen, it announced on Monday, which is a UK biotechnology company working on Bacillus and its applications.

Read more
11 Aug 2020 12:36

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

Read more
27 Jul 2020 21:28

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
9 Jun 2020 15:51

Destiny Pharma awarded grant for Cardiff research collaboration

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has been jointly awarded a National Biofilms Innovation Centre (NBIC) grant to fund a research collaboration with Cardiff University, it announced on Tuesday.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
3 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
4 May 2020 12:24

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Read more
3 Mar 2020 16:16

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Read more
20 Jan 2020 11:44

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.